Skip to Content

Generic Ximino Availability

Ximino is a brand name of minocycline, approved by the FDA in the following formulation(s):

XIMINO (minocycline hydrochloride - capsule, extended release;oral)

  • Manufacturer: SUN PHARM INDS LTD
    Approval date: July 11, 2012
    Strength(s): EQ 45MG BASE, EQ 67.5MG BASE, EQ 90MG BASE, EQ 112.5MG BASE, EQ 135MG BASE

Has a generic version of Ximino been approved?

No. There is currently no therapeutically equivalent version of Ximino available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ximino. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method for the treatment of acne
    Patent 5,908,838
    Issued: June 1, 1999
    Inventor(s): Gans; Eugene H.
    Assignee(s): Medics Pharmaceutical Corporation
    A method for the treatment of acne is provided which results in the reduction of vestibular side effects following administration of oral tetracycline antibiotics.
    Patent expiration dates:
    • February 19, 2018
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
  • Minocycline oral dosage forms for the treatment of acne
    Patent 7,541,347
    Issued: June 2, 2009
    Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
    Assignee(s): Medicis Pharmaceutical Coropration
    Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Patent expiration dates:
    • April 2, 2027
      ✓ 
      Patent use: TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
  • Minocycline oral dosage forms for the treatment of acne
    Patent 7,544,373
    Issued: June 9, 2009
    Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
    Assignee(s): Medicis Pharmaceutical Corporation
    Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Patent expiration dates:
    • April 2, 2027
      ✓ 
      Drug product
  • Minocycline oral dosage forms for the treatment of acne
    Patent 7,790,705
    Issued: September 7, 2010
    Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
    Assignee(s): Medicis Pharmaceutical Corporation
    Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Patent expiration dates:
    • June 24, 2025
      ✓ 
      Patent use: TREATMENT OF ACNE
  • Method for the treatment of acne
    Patent 7,919,483
    Issued: April 5, 2011
    Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
    Assignee(s): Medicis Pharmaceutical Corporation
    A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.
    Patent expiration dates:
    • March 7, 2027
      ✓ 
      Patent use: TREATMENT OF ACNE
  • Minocycline oral dosage forms for the treatment of acne
    Patent 8,252,776
    Issued: August 28, 2012
    Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
    Assignee(s): Medicis Pharmaceutical Corporation
    Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Patent expiration dates:
    • June 24, 2025
      ✓ 
      Patent use: TREATMENT OF ACNE
  • Minocycline oral dosage forms for the treatment of acne
    Patent 8,268,804
    Issued: September 18, 2012
    Inventor(s): Wortzman; Mitchell & Plott; R. Todd & Bhatia; Kuljit & Patel; Bhiku
    Assignee(s): Medicis Pharmaceutical Corporation
    Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Patent expiration dates:
    • June 24, 2025
      ✓ 
      Patent use: TREATMENT OF ACNE
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide